American Society of Hematology

SHERPA: Blue

People

  1. Epstein-Peterson
    Epstein-Peterson
  2. Moskowitz
    Moskowitz
  3. Horwitz
    Horwitz
  4. Kumar
    Kumar
  5. Palomba
    Palomba
  6. Salles
    Salles
  7. Stuver
    Stuver
  8. Zelenetz
    Zelenetz
  9. Johnson
    Johnson
  10. Falchi
    Falchi

Groups

  1. Hematologic Malignancies, Division of (55)
  2. Hematology-Oncology Fellows (55)
  3. Weinberg Fellows (55)
  4. Center for Hematologic Malignancies (53)
  5. Department of Medicine (53)
  6. Lymphoma (40)
  7. Population Sciences Research Program (33)
  8. Department of Pathology and Laboratory Medicine (30)
  9. Sloan Kettering Institute Postdocs (29)
  10. GME, Medicine (28)
Search Within
  1. "Zachary Epstein-Peterson"
Formats
  1. Meeting Abstract (49)
  2. Journal Article (5)
  3. Review (1)
Groups
  1. Hematologic Malignancies, Division of (55)
  2. Hematology-Oncology Fellows (55)
  3. Weinberg Fellows (55)
  4. Center for Hematologic Malignancies (53)
  5. Department of Medicine (53)
  6. Lymphoma (40)

More Groups

People
  1. Zachary Epstein-Peterson (55)
  2. Alison Moskowitz (30)
  3. Steven Horwitz (29)
  4. Anita Kumar (27)
  5. Gilles Salles (27)
  6. Maria Palomba (27)

More People

Years
  1. 2024 (18)
  2. 2023 (14)
  3. 2022 (7)
  4. 2021 (2)
  5. 2020 (4)
  6. 2019 (5)

More Years

Publications
  1. Blood (49)
  2. Blood Advances (5)
  3. Hematology-American Society of Hematology Education Program (1)

Results (55)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Rituximab plus /- ibrutinib as first line therapy for marginal zone lymphoma
    Meeting Abstract

    Noy, A.; Thet, W. S.; Vemuri, S.; Seshan, V.; Batlevi, C. L.; Epstein-Peterson, Z. D.; Falchi, L.; Ghione, P.; Habermann, T. M.; Hamlin, P. A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Sequential R-CHOP/(R)-ICE and dose-adjusted EPOCH-R are both appropriate frontline treatments for newly diagnosed primary mediastinal B-cell lymphoma: Results of a retrospective analysis
    Meeting Abstract

    Bantilan, K. S.; Luttwak, E.; Moskowitz, C. H.; Matasar, M.; Straus, D. J.; Portlock, C. S.; Moskowitz, A.; Noy, A.; Palomba, M. L.; Horwitz, S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Angioimmunoblastic versus non-angioimmunoblastic nodal T-follicular helper cell lymphomas: Single center retrospective analysis on 208 cases
    Meeting Abstract

    Sordi, B.; Eren, O. C.; Ganesan, N.; Iyengar, V.; Stuver, R.; Johnson, W. T.; Moskowitz, A.; Ghione, P.; Galasso, N.; Casper, E.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • A prospective geriatric assessment (GA) study predicting toxicities in older adults (OA) with non-Hodgkin Lymphoma (NHL): Timed up and go test (TUG) time emerges as a functional vital sign
    Meeting Abstract

    Torka, P.; Drill, E.; Ganesan, N.; Truong, R.; Qiu, A.; Amador, W. R.; Oliveros, M.; Boardman, A. P.; Caron, P.; David, K. A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Pembrolizumab and involved site radiation therapy alone as an alternative to transplant in patients with localized failure following chemotherapy for Hodgkin Lymphoma: A prospective multicenter phase II study
    Meeting Abstract

    Dreyfuss, A.; Ganesan, N.; Alencar, A. J.; Boardman, A. P.; Caron, P.; Chang, T.; Davey, T.; David, K. A.; Dogan, A.; Epstein-Peterson, Z. D.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Safety, pharmacokinetics, pharmacodynamics and clinical activity of KT-333, a targeted protein degrader of STAT3, in patients with relapsed or refractory lymphomas, leukemia, and solid tumors
    Meeting Abstract

    Feldman, T.; Marchi, E.; Smith, S. D.; Olszewski, A. J.; Huen, A. O.; Epstein-Peterson, Z. D.; Stevens, D. A.; Starodub, A. N.; Feldman, E. J.; Rodriguez, C. P.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Improved outcomes for primary refractory classical Hodgkin Lymphoma: A retrospective analysis
    Meeting Abstract

    Santarosa, A. M.; Ganesan, N.; Chang, T.; Hannigan, K.; Casper, E.; Shah, G. L.; Boardman, A. P.; Caron, P.; David, K. A.; Dogan, A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Real-world outcomes of frontline polatuzumab and impact of frailty in older adults with newly diagnosed diffuse large B-cell lymphoma (DLBCL)
    Meeting Abstract

    Iyengar, V.; Chicola, J.; Joseph, A.; Okwali, M.; Truong, R.; Bapodra, N.; Boardman, A. P.; Caron, P.; David, K. A.; Epstein-Peterson, Z. D.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in treatment-naive chronic lymphocytic leukemia: 5-Year follow up, retreatment outcomes, and Impact of MRD kinetics (ΔMRD400)
    Meeting Abstract

    Soumerai, J. D.; Dogan, A.; Seshan, V.; Flaherty, K. L.; Slupe, N.; Carter, J.; Hochberg, E.; Barnes, J. A.; Abramson, J. S.; Hamilton, A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • High grade B-cell lymphoma with MYC/BCL6-rearrangements (R) may have inferior outcomes compared to BCL2-R disease
    Meeting Abstract

    Healton, S. E.; Luttwak, E.; Rivas-Delgado, A.; Boardman, A. P.; Caron, P.; David, K. A.; Epstein-Peterson, Z. D.; Falchi, L.; Ghione, P.; Hamlin, P. A.; more...
    Blood (2024)

    Fulltext@MSK | Save